Contraception

New Drug Application Submitted for Intrauterine Contraceptive

Published in Women's Health Weekly, February 19th, 2000

Berlex Laboratories, Inc., Wayne, New Jersey, announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Mirena (levonorgestrel-releasing intrauterine contraceptive).

Mirena is a unique intrauterine contraceptive that delivers a small dose of locally-acting hormone directly in the uterus.

In 1999 more than 850,000 women in the U.S. opted for a method of long-acting contraception. The majority of these women chose a generally non-reversible method: surgical sterilization. Today, more than 1,400,000 women in Europe, Asia and Latin America use Mirena as an option for long-acting (5-year) reversible...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2000-02-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry